Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about TRAW, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Any approved or standard-of-care therapy | Myelodysplastic Syndrome | Phase 3 · NCT02562443 | Terminated |
| Rigosertib Sodium | Myelodysplastic Syndromes | Phase 3 · NCT01928537 | Completed |
| Rigosertib | Myelodysplastic Syndrome | Phase 3 · NCT02562443 | Terminated |
| ON 01910.Na Concentrate | Myelodysplastic Syndrome | Phase 1/2 · NCT00867061 | Withdrawn |
| TRX-100 | Influenza | Phase 2 · NCT07371650 | Active not recruiting |
| Ratutrelvir (83-0060) non-randomised | COVID - 19 | Phase 2 · NCT07157007 | Completed |
| Ratutrelvir | COVID - 19 | Phase 2 · NCT07157007 | Completed |
| Narazaciclib (ON123300) | Endometrioid Endometrial Cancer | Phase 1/2 · NCT05705505 | Unknown |
| Influenza A/France/759/2021 (H1N1) virus | Influenza | Phase 2 · NCT07503405 | Not yet recruiting |
| Briciclib Sodium (ON 013105) | Lymphoma | Phase 1 · NCT01049113 | Terminated |
| Irinotecan | Hepatoma | Phase 1 · NCT00861783 | Completed |
| 83-0060 | Healthy Volunteers Only | Phase 1 · NCT06402136 | Completed |
| Briciclib | Neoplasms | Phase 1 · NCT02168725 | Terminated |
Also used in these trials (approved or third-party drugs, not TRAW's own candidates): Gemcitabine Hydrochloride, Azacitidine, Nirmatrelvir And Ritonavir, Nivolumab, Letrozole, Cisplatin.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
TRAW holds $5M in cash and short-term investments (as of Jun 30, 2026) and burns about $5M/quarter from operations, an estimated runway of 3 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 90 · High
These conditions raise substantial doubt about our ability to continue as a going concern through the one-year period after the date that the financial statements are issued.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when TRAW files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Sirenia Capital Management LP | Institution (13G, 5%+) | 6,565,474 | 42.72% | 2026-06-30 |
| Ikarian Capital, LLC | Institution (13G, 5%+) | 1,555,423 | 10.12% | 2026-06-30 |
| ORBIMED ADVISORS LLC 10% owner · +2.99M options |
Insider | 1,203,250 | 7.83% | 2026-04-16 |
| Perceptive Advisors LLC | Institution (13G, 5%+) | 979,815 | 6.38% | 2026-03-31 |
| Iain D. Dukes Chief Executive Officer, Director · +717,946 options |
Insider | 171,130 | 1.11% | 2025-12-12 |
| Nikolay Savchuk Chief Operating Officer, Director · +278,010 options |
Insider | 150,606 | 0.98% | 2025-12-12 |
| Charles David Pauza Chief Science Officer Virology · +321,659 options |
Insider | 115,971 | 0.75% | 2025-12-12 |
| Robert Redfield Chief Medical Officer · +290,936 options |
Insider | 113,919 | 0.74% | 2025-12-12 |
| Werner Cautreels Director · +76,434 options |
Insider | 109,222 | 0.71% | 2025-12-12 |
| Charles Nolan Parker Chief Financial Officer · +288,521 options |
Insider | 15,393 | 0.10% | 2025-10-12 |
| Mary Teresa Shoemaker Director · +83,744 options |
Insider | 6,292 | 0.04% | 2025-12-12 |
| Jack E Stover Director · +83,744 options |
Insider | 6,165 | 0.04% | 2025-12-12 |
Share count 15,368,277 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for TRAW and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →